1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Japan Academia Progresses Novel Melanoma Drug Despite Pharma 'Reluctance'

Promising Phase II Results

 
• By Lisa Takagi

Academia-developed novel oral PAI-1 inhibitor in combination with Opdivo showed a strong response rate in PD-1 treated melanoma patients with certain disease characteristics and could represent a new breakthrough for a class with no clinical stage competitors. 

National funding and an original research collaboration platform by dermatologists made the Japanese P2 successful.
National funding and an original research collaboration platform by dermatologists made the Japanese P2 successful. • Source: Shutterstock

A novel molecule originated by Japanese academia has recorded an unusual success in a Phase II trial for a challenging dermatologic oncology indication, and appears to be the only drug globally in its class to be in active clinical development.

Tohoku University recently announced positive top-line results from the investigator-led, 34-patient study for its in-house-developed oral plasminogen activator inhibitor-1 (PAI-1) inhibitor TM5614 in combination with Ono Pharmaceutical Company, Ltd

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia